CPX-351 versus venetoclax plus hypomethylating agents for newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis

Key Points

• CPX-351 shows a superior effectiveness in treating acute myeloid leukemia compared to venetoclax and hypomethylating agents.
• In the analysis, CPX-351 led to improved outcomes in overall survival and remission rates.
• Meta-analysis examined multiple studies, highlighting differences in treatment response rates between the two regimens.
• These findings suggest potential shifts in treatment strategies for acute myeloid leukemia, emphasizing a need for further clinical validation.